Cargando…
Inhaled Sargramostim (Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor) for COVID-19-Associated Acute Hypoxemia: Results of the Phase 2, Randomized, Open-Label Trial (iLeukPulm)
INTRODUCTION: Granulocyte-macrophage colony-stimulating factor (GM-CSF), a protein produced in the lung, is essential for pulmonary host defense and alveolar integrity. Prior studies suggest potential benefits in several pulmonary conditions, including acute respiratory distress syndrome and viral i...
Autores principales: | Paine, Robert, Chasse, Robert, Halstead, E Scott, Nfonoyim, Jay, Park, David J, Byun, Timothy, Patel, Bela, Molina-Pallete, Guido, Harris, Estelle S, Garner, Fiona, Simms, Lorinda, Ahuja, Sanjeev, McManus, John L, Roychowdhury, Debasish F |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10363010/ https://www.ncbi.nlm.nih.gov/pubmed/36458916 http://dx.doi.org/10.1093/milmed/usac362 |
Ejemplares similares
-
279. Inhaled Sargramostim (rhu GM-CSF) Leads to Enhanced SARS-CoV-2 Virus-Specific Immune Response and Viral Clearance: Results of the Biomarker Cohort of a Randomized, Double-Blind, Placebo-Controlled Phase 2b Trial in Non-Hospitalized Patients with COVID-19
por: Joshi, Ila, et al.
Publicado: (2023) -
Boosting Abscopal Response to Radiotherapy with Sargramostim: A Review of Data and Ongoing Studies
por: Leary, Robyn, et al.
Publicado: (2019) -
Some Account of the Baths of Leuk in the Valais
por: Reeve, Henry
Publicado: (1807) -
Safety and efficacy of sargramostim (GM‐CSF) in the treatment of Alzheimer's disease
por: Potter, Huntington, et al.
Publicado: (2021) -
Monocyte biomarkers define sargramostim treatment outcomes for Parkinson's disease
por: Abdelmoaty, Mai M., et al.
Publicado: (2022)